XML 113 R94.htm IDEA: XBRL DOCUMENT v3.25.1
Cash and cash equivalents - Additional Information (Details)
€ in Thousands, $ in Millions
1 Months Ended 12 Months Ended
Nov. 18, 2024
EUR (€)
Nov. 18, 2024
USD ($)
Oct. 11, 2024
USD ($)
Dec. 29, 2023
EUR (€)
Dec. 29, 2023
USD ($)
Oct. 18, 2023
EUR (€)
Oct. 18, 2023
USD ($)
Jul. 19, 2023
EUR (€)
Jul. 19, 2023
USD ($)
Nov. 04, 2022
EUR (€)
Nov. 04, 2022
USD ($)
Dec. 31, 2024
EUR (€)
Oct. 31, 2024
EUR (€)
Jul. 31, 2024
EUR (€)
Dec. 31, 2024
EUR (€)
Dec. 31, 2023
EUR (€)
Dec. 31, 2022
EUR (€)
Dec. 31, 2021
EUR (€)
Cash and Cash Equivalents                                    
Cash and cash equivalents                       € 96,564     € 96,564 € 26,918 € 86,736 € 86,553
Decrease in cash and cash equivalents                             69,600      
Net cash used in operating activities                             (85,928) (81,614) (44,928)  
Net cash generated by investing activities                             8,745 (7,731) 8,868  
Net cash generated by financing activities                             145,592 29,081 37,268  
Issue of royalty certificates                             20,100 5,100    
Gross proceeds from issuance of ordinary shares and prefunded warrants [1]                             57,338 30,589 8,827  
Issue of equity                             57,338 30,587 9,366  
Share capital                                    
Cash and Cash Equivalents                                    
Issue of equity                             € 425 € 96 € 13  
Tranche I, 2024 Financing arrangement in three tranches                                    
Cash and Cash Equivalents                                    
Issue of royalty certificates                           € 20,100        
Net proceeds from issuance of royalty certificates                           € 19,700        
Gross proceeds from issuance of ordinary shares and prefunded warrants                         € 94,100          
Net proceeds from issuance of ordinary shares and prefunded warrants                         € 86,200          
Tranche II, 2024 Financing arrangement in three tranches                                    
Cash and Cash Equivalents                                    
Gross proceeds from issuance of ordinary shares and prefunded warrants                       21,400            
Net proceeds from issuance of ordinary shares and prefunded warrants                       € 19,800            
Licensing and collaboration agreement with CTTQ                                    
Cash and Cash Equivalents                                    
Milestone payment | $     $ 10.0                              
Amount received attributable to withholding taxes € 1,000 $ 1.0   € 300 $ 0.3     € 200 $ 0.2 € 1,300 $ 1.3              
Licensing agreement with Hepalys                                    
Cash and Cash Equivalents                                    
Upfront payment received           € 9,500 $ 10.0                      
[1] Including subscriptions to BSA share warrants for €6 thousand, €2 thousand, and €0 thousand for the period ended December 31, 2024, December 31, 2023, and December 31, 2022, respectively.